Demographics and characteristics of SCD patients and healthy controls for direct and indirect platelet tests
| Variable . | Healthy controls . | SCD steady state . | SCD acute pain crisis . |
|---|---|---|---|
| Direct tests | |||
| No. of subjects | 13 | 24 | 10 |
| Age, median (IQR), y | 46 (26-52) | 36 (27-46) | 34 (28-38) |
| Females, n (%) | 7 (53.8) | 16 (66.7) | 8 (80) |
| No. on hydroxyurea (%) | 0 (0) | 20 (83.3) | 6 (60) |
| Hemoglobin, median (IQR), g/dL | 12.6 (11.7-14.8) | 8.8 (8.0-9.3) | 7.8 (7.0-8.9) |
| Reticulocyte count, median (IQR), % | 1.91 (1.36-2.36) | 9.31 (5.81-12.23) | 9.74 (7.96-13.65) |
| White blood cell count, median (IQR), ×109/L | 6.66 (5.01-8.22) | 7.25 (4.61-8.39) | 8.21 (6.64-14.33) |
| Platelet count, median (IQR), ×109/L | 271 (217-371) | 257 (162-355) | 359 (244-483) |
| Total bilirubin, median (IQR), mg/dL | 0.4 (0.3-0.6) | 1.8 (1.1-2.7) | 2.4 (1.7-3.9) |
| Lactate dehydrogenase, median (IQR), U/L | 194 (177-244) | 342 (201-503) | 294 (230-397) |
| High-sensitive C-reactive protein, median (IQR), mg/L | 2.7 (0.7-6.1) | 3.6 (1.3-6.6) | 6.5 (3.1-17.8) |
| Indirect tests | |||
| No. of subjects | 13 | 20 | 20 |
| Age, median (IQR), y | 46 (26-52) | 35 (29-41) | 35 (29-41) |
| Females, n (%) | 7 (53.8) | 14 (70) | 14 (70) |
| No. on hydroxyurea (%) | 0 (0) | 16 (80) | 16 (80) |
| Hemoglobin, median (IQR), g/dL | 12.6 (11.7-14.8) | 9.1 (8.0-9.8) | 8.1 (7.6-9.3) |
| Reticulocyte count, median (IQR), % | 1.91 (1.36-2.36) | 7.39 (5.77-12.09) | 9.24 (6.96-11.72) |
| White blood cell count, median (IQR), ×109/L | 6.66 (5.01-8.22) | 6.69 (4.89-8.80) | 7.10 (6.28-13.79) |
| Platelet count, median (IQR), ×109/L | 271 (217-371) | 310 (216-453) | 319 (224-454) |
| Total bilirubin, median (IQR), mg/dL | 0.4 (0.3-0.6) | 1.8 (1.3-2.3) | 1.7 (1.3-2.5) |
| Lactate dehydrogenase, median (IQR), U/L | 194 (177-244) | 317 (199-542) | 327 (224-508) |
| High-sensitive C-reactive protein, median (IQR), mg/L | 2.7 (0.7-6.1) | 4.0 (1.3-5.8) | 4.2 (1.2-9.9) |
| Variable . | Healthy controls . | SCD steady state . | SCD acute pain crisis . |
|---|---|---|---|
| Direct tests | |||
| No. of subjects | 13 | 24 | 10 |
| Age, median (IQR), y | 46 (26-52) | 36 (27-46) | 34 (28-38) |
| Females, n (%) | 7 (53.8) | 16 (66.7) | 8 (80) |
| No. on hydroxyurea (%) | 0 (0) | 20 (83.3) | 6 (60) |
| Hemoglobin, median (IQR), g/dL | 12.6 (11.7-14.8) | 8.8 (8.0-9.3) | 7.8 (7.0-8.9) |
| Reticulocyte count, median (IQR), % | 1.91 (1.36-2.36) | 9.31 (5.81-12.23) | 9.74 (7.96-13.65) |
| White blood cell count, median (IQR), ×109/L | 6.66 (5.01-8.22) | 7.25 (4.61-8.39) | 8.21 (6.64-14.33) |
| Platelet count, median (IQR), ×109/L | 271 (217-371) | 257 (162-355) | 359 (244-483) |
| Total bilirubin, median (IQR), mg/dL | 0.4 (0.3-0.6) | 1.8 (1.1-2.7) | 2.4 (1.7-3.9) |
| Lactate dehydrogenase, median (IQR), U/L | 194 (177-244) | 342 (201-503) | 294 (230-397) |
| High-sensitive C-reactive protein, median (IQR), mg/L | 2.7 (0.7-6.1) | 3.6 (1.3-6.6) | 6.5 (3.1-17.8) |
| Indirect tests | |||
| No. of subjects | 13 | 20 | 20 |
| Age, median (IQR), y | 46 (26-52) | 35 (29-41) | 35 (29-41) |
| Females, n (%) | 7 (53.8) | 14 (70) | 14 (70) |
| No. on hydroxyurea (%) | 0 (0) | 16 (80) | 16 (80) |
| Hemoglobin, median (IQR), g/dL | 12.6 (11.7-14.8) | 9.1 (8.0-9.8) | 8.1 (7.6-9.3) |
| Reticulocyte count, median (IQR), % | 1.91 (1.36-2.36) | 7.39 (5.77-12.09) | 9.24 (6.96-11.72) |
| White blood cell count, median (IQR), ×109/L | 6.66 (5.01-8.22) | 6.69 (4.89-8.80) | 7.10 (6.28-13.79) |
| Platelet count, median (IQR), ×109/L | 271 (217-371) | 310 (216-453) | 319 (224-454) |
| Total bilirubin, median (IQR), mg/dL | 0.4 (0.3-0.6) | 1.8 (1.3-2.3) | 1.7 (1.3-2.5) |
| Lactate dehydrogenase, median (IQR), U/L | 194 (177-244) | 317 (199-542) | 327 (224-508) |
| High-sensitive C-reactive protein, median (IQR), mg/L | 2.7 (0.7-6.1) | 4.0 (1.3-5.8) | 4.2 (1.2-9.9) |
Age is that at the time of blood collection. For the direct tests, assays were performed with platelets isolated within 2 hours of blood collection. For the indirect tests, platelets from healthy subjects were incubated for 1 hour with PPP from SCD patients or healthy controls.